A new long-acting glucagon-like peptide-1 (GLP-1) analogue from Novo Nordisk for glycemic control in adults with type 2 diabetes who have received metformin and/or sulfonylureas in addition to diet control and exercise. And reduce the risk of major cardiovascular adverse events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes with cardiovascular disease.
This product is colorless or almost colorless clear isotonic liquid; pH=7.4.
Fold edit this paragraph for indications This product is suitable for glycemic control in adults with type 2 diabetes: adults with type 2 diabetes who are treated with metformin and/or sulfonylurea on the basis of diet control and exercise and still have poor glycemic control.
It is indicated to reduce the risk of major cardiovascular adverse events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus with cardiovascular disease.
Fold and edit this section specification The specifications of this product are: